Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:54:51 2024-05-24 pm EDT			5-day change	1st Jan Change
0.017 ^USD	+2.41%		-.--%	-95.88%

May. 23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI

Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

March 27, 2023 at 07:16 am EDT

Gamida Cell Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 79.38 million compared to USD 89.79 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to USD 1.52 a year ago.

Latest news about Gamida Cell Ltd.

Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	Apr. 09	CI
Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	Apr. 04	CI
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
Top Premarket Decliners	Mar. 28	MT
Top Midday Decliners	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Transcript : Gamida Cell Ltd., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	Mar. 27	MT
Top Premarket Decliners	Mar. 27	MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Gamida Cell Ltd. Announces Cessation of Executives	Mar. 27	CI
Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC	Mar. 26	CI
JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	Jan. 29	MT
Gamida Cell Exploring Strategic Alternatives; Shares Rise	Jan. 29	MT
Gamida Cell Actively Pursuing Strategic Alternatives	Jan. 28	CI
Transcript : Gamida Cell Ltd. - Special Call	Dec. 04
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	Nov. 15	MT
Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director	Nov. 15	CI
Transcript : Gamida Cell Ltd., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting	Nov. 04	CI
Transcript : Gamida Cell Ltd. - Shareholder/Analyst Call	23-10-19
Gamida Cell Reports New Early Data in Phase 1 Study of Cancer Treatment Candidate	23-10-16	MT

Chart Gamida Cell Ltd.

Duration

Period

More charts

Company Profile

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GAMIDA CELL LTD.	-95.88%	2.62M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.06%	21.96B
GENMAB A/S	-9.37%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs